Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Conclusions
Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments.
Trial registration number
NCT01491815.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Ostergaard, M., van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordström, D. C., Nurmohamed, M. T., Gudbjornsson, B., Ornbjerg, L. M., Boyesen, P., Lend, K., Horslev-Petersen, K., Uhlig, T., Sokka, T., Grondal, G., Krabbe, S., Tags: Editor's choice, ARD, Rheumatoid arthritis Source Type: research
More News: Abatacept | Actemra | Arthritis | Hydroxychloroquine | Methotrexate | Orencia | Prednisolone | Radiography | Rheumatoid Arthritis | Rheumatology | Study